CLEAR·OCEAN

Kura Oncology, Inc. (KURA): insiders bought $1,112,000 in open-market purchases, SEC filings show

August 18, 2026 · Automated from SEC filings

1 insider at Kura Oncology, Inc. (KURA) reported open-market stock purchases totaling $1,112,000 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from WILSON TROY EDWARD (director, officer: President and CEO), who acquired 100,000 shares at $11.12 on August 17, 2026.

Reported open-market purchases

Source: SEC Form 4. Option grants and tax-withholding sales are excluded.

DateInsiderRoleSharesPriceValueSource
2026-08-17WILSON TROY EDWARDdirector, officer: President and CEO100,000$11.12$1,112,000SEC Form 4

About the company

Kura Oncology, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $1.0B, with shares trading near $11.28.

Sources

This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.